Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.
NCT06195683
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
23
Enrollment
OTHER
Sponsor class
Conditions
Non-small Cell Lung Cancer
PDL1 Gene Mutation
Interventions
DRUG:
Serplulimab
Sponsor
Zhejiang Cancer Hospital